As the quality of visual recognition software continues to improve, privacy concerns have grown concomitantly. Because we now document our lives with so many pictures posted to social media—Facebook hosts over 250 billion photos, with 350 million new photos added every day—photographs are becoming hugely important to the big data movement.
FTC Examines Pre-Download Consumer Disclosures of Mobile Shopping Applications; Makes Recommendations Applicable to All Consumer Data
Continuing its examination of consumer protection issues in the mobile payments sphere, on August 1, 2014, the FTC released a staff report examining the pre-download disclosures of mobile shopping applications to evaluate the information provided to consumers about…
San Francisco-based software provider Splunk’s data collection and analysis product, Splunk Enterprise, was an almost instant hit upon its debut in 2006.
The evidence is mounting that Edward Snowden and his journalist allies have helped al Qaeda improve their security against NSA surveillance.
As part of a drug trafficking investigation the US government persuaded a Court to issue a warrant that “purports to authorize the Government to search any and all of Microsoft’s facilities worldwide” according to Microsoft’s opposition brief filed on June 6, 2014 in the US District Court for the Southern District of New York.
The year 2014 is on track to be the most active IPO market in the United States since 2000, with the mid-year total number of IPOs topping last year’s mid-year total by more than 60%.
The idea that video games can impart real-world skills has been around almost as long as video games themselves.
On Saturday, August 2, the North Carolina General Assembly gave final approval to the Appropriations Act of 2014.
Earlier this week, a popular source of regulatory news published an article claiming FDA “finalized a new rule this week that prohibits manufacturers from using so-called “split-predicates”.
Justice Roger T. Hughes of the Federal Court of Canada granted AbbVie the first-ever limited injunction against a branded pharmaceutical company infringing a branded competitor’s patent.